The search for biomarkers to enable detection and monitoring of disease progression from NAFLD to NASH and NASH itself; the Amsterdam NASH cohort

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON19935

Enrollment

1100

Registered

2018-04-03

Start date

2018-04-01

Completion date

Unknown

Last updated

2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NAFLD, NASH

Interventions

Ultrasound guided liver biopsy

Eligibility

Inclusion criteria

Inclusion criteria: • Diagnosis of steatosis hepatis on ultrasound or by biopsy • >18 years of age • Transaminases ALAT and ASAT above upper limit (50U/L) • BMI > 30 kg/ m²

Exclusion criteria

Exclusion criteria: • Abusive alcohol use (>20 IU/week) • Hepatitis B and/or C • Auto-immune hepatitis • Wilsons disease/ alpha-1-antitripsine deficiency • Hemochromatosis • Bleeding disorder • Use of drugs with a potential role in aggravation of pre-existing NAFLD • Not able or willing to undergo MRI (for example claustrophobia, ICD, pacemaker) • Diagnosis of liver cirrhosis and/or hepatocellular carcinoma

Design outcomes

Primary

Measure	Time frame
to identify and validate noninvasive diagnostic methods (imaging and molecular markers) in disease progression from NAFLD to NASH as well as progression of NASH itself	—

Secondary

Measure	Time frame
to apply a systems biology approach to identify the hierarchy of driving mechanisms (microbial and metabolic markers) involved in the conversion of NAFLD-NASH and NASH-cirrhosis after 5 years	—

Contacts

Public ContactM. Nieuwdorp

AFDELING INWENDIGE GENEESKUNDE AMC MEIBERGDREEF 9, KAMER F4.159.2

m.nieuwdorp@amc.uva.nl+31 (0)20 5666612

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)